Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Finished

CURE-PDAC Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)

Coordinator
Ionctura BV, Netherlands
Runs
1 October 2022 to 31 March 2025
Status
Finished
EU funding
€2.5m
Total cost
€5.9m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190159801

What the project is doing

In the project's own words, from its summary on CORDIS.

iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patents with unmet medical needs. iOnctura’s unique pipeline of drugs unlock mechanisms at the tumour-stroma-immune (T-S-I) interface, a multi cell-network that is responsible for driving tumour growth and survival as well as treatment resistance. Pancreatic cancer is one of the most lethal cancers associated with devastating impact on the quality of life of patients; current treatments are largely ineffective and there is a need for game-changing therapies.

IOA-289, is a first in class autotaxin (ATX) inhibitor that tackles cancer growth and spread by affecting core mechanisms at the T-S-I interface. The EIC Accelerator funding for CURE-PDAC will allow iOnctura to accelerate the clinical development of IOA-289 as a treatment for pancreatic cancer through Phase I/II clinical trials, reach a major value inflection point and attract further financial investment into the company.

Topics

Who is involved

OrganisationCityCountryRole
Ionctura BVAmsterdamNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI